Accumulating evidence shows that Curcumin may prevent colon cancer

April 25, 2007

Using chemopreventive agents (any agent, whether natural or made in a lab that helps prevent cancer) to delay or prevent cancer is the most practical way to reduce morbidity and mortality (disease and death). This necessitates that safer compounds, especially those derived from natural sources must be examined. In preclinical studies in a variety of cancer cell lines including cancers of the breast, cervix, colon, stomach, liver, leukemia, the mouth, ovaries, pancreatic, and prostate have consistently shown that Curcumin (from Turmeric) possesses anti-cancer activity in vitro and in pre-clinical animal studies. The robust activity of Curcumin in colorectal cancer has led to five phase 1 human clinical trials being completed that show the safety and tolerability of Curcumin in colorectal cancer patients. Trials using up to 8000mg a day still demonstrate safety. The success of these trials has led to the development of phase II trials that are currently enrolling patients. Overwhelming in-vitro evidence and completed clinical trials suggests that Curcumin may be useful for preventing colon cancer in humans. The pre-clinical and clinical evidence and review was performed by scientists at the University of Wisconsin, School of Pharmacy, and the University of Wisconsin, School of Medicine and Public Health and is published in the April 18th, 2007 issue of the Journal Cancer Letters.